Loading...
Market
Next region to approve DFNB9 gene therapy by end of 2025
5
Resolution / Starting Odds
United States • 25%
European Union • 25%
Japan • 25%
South Korea • 25%
Official announcements from regional regulatory authorities (e.g., FDA, EMA)
Story
Gene Therapy in China Restores Hearing in Five Deaf Children
Jun 5, 2024, 09:20 AM
A pioneering gene therapy trial in China has successfully restored hearing in both ears of children who were born deaf. The trial, which involved five children, provided a normal copy of a mutated gene, specifically targeting a condition called DFNB9 caused by Otof mutations. This condition accounts for 2-8% of all congenital hearing loss. As a result of the therapy, the children can now listen and dance to music. The study was published in Nature Medicine and The Lancet.
View original story
Similar markets
Successful phase 3 trial by another company • 25%
New regulatory approval • 25%
Major partnership or acquisition • 25%
Another failed trial • 25%
USA • 25%
China • 25%
Germany • 25%
UK • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
USA • 25%
China • 25%
UK • 25%
Germany • 25%
Yes • 50%
No • 50%
USA • 25%
India • 25%
Germany • 25%
Japan • 25%
0 countries • 20%
1-3 countries • 20%
4-6 countries • 20%
7-9 countries • 20%
10 or more countries • 20%
EU • 33%
Asia • 33%
South America • 33%
FDA (USA) • 33%
EMA (Europe) • 33%
WHO • 33%
Success • 33%
Partial Success • 33%
Failure • 33%